Novomix 30 Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novomix 30 Flexpen, is a rapid‑acting insulin analog presented as a prefilled FlexPen (30 units per dose) for subcutaneous injection use. It is indicated for improving post‑prandial glucose control in adults with type 1 or type 2 diabetes.

GNH USA supplies Novomix 30 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products. Our distribution network ensures timely delivery across EU and other regulated markets.

Novomix 30 Flexpen, containing insulin aspart, is used in the management of diabetes mellitus, a disorder of glucose regulation.

- Type 1 diabetes mellitus: provides rapid post‑prandial glucose reduction as part of a basal‑bolus regimen. - Type 2 diabetes mellitus: used for mealtime insulin coverage when oral agents are insufficient. - Insulin pump therapy: serves as a rapid‑acting insulin source for continuous subcutaneous infusion in selected patients.

Insulin aspart may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase associated with improved glycemic control. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Mild allergic reactions: rash or urticaria. - Edema: peripheral swelling in some patients.

Serious or Rare Side Effects: - Severe hypoglycemia: neurological impairment requiring immediate assistance. - Anaphylactic reaction: rare but potentially life‑threatening allergic response. - Hypokalemia: low potassium levels, particularly with prolonged hypoglycemia. - Acute insulin allergy: systemic symptoms such as fever or joint pain. - Serum insulin antibodies: may alter insulin action and cause unpredictable glucose control.

When using Novomix 30 Flexpen, consider the following safety measures.

- Blood glucose monitoring: check levels before each dose and adjust as needed. - Hypoglycemia risk: avoid dosing when glucose is low and have fast‑acting carbohydrates available. - Illness and stress: may require dose adjustments during acute illness or increased stress. - Renal or hepatic impairment: use with caution and consider reduced dosing. - Pregnancy and lactation: discuss benefits and risks with a healthcare professional. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin aspart can interact with several medicines, influencing glucose control or safety.

Major Interactions (Avoid): - Sulfonylureas: combined use increases risk of severe hypoglycemia. - Beta‑blockers: may mask symptoms of hypoglycemia, requiring closer monitoring. - Alcohol: can potentiate hypoglycemic effects, especially with inadequate food intake.

Moderate Interactions (Monitor Closely): - Thiazolidinediones: additive effect on fluid retention and edema. - ACE inhibitors: may enhance insulin sensitivity, necessitating dose review. - MAO inhibitors: potential for unpredictable glycemic control.